Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
The company's filing for a variation of existing marketing authorisation aligns with guidance from the EMA and the World Health Organization to update vaccines to target the JN.1 lineage for autumn 2024. According to nonclinical studies, the Novavax JN.1 Covid-19 vaccine elicited a broad neutralising response against JN.1 lineage viruses, including those with the F456L and R346T mutations and the FLiRT and FLuQE variants. The vaccine also generates robust Th1-biased CD4+ T cell responses to JN.1 lineage variants. NVX-CoV2705 specifically targets the parent strain of the KP.2 and KP.3.2 lineages. Novavax aims to make the vaccine available in unit-dose vials for distribution within the European Union on receipt of approval. The company has also sought authorisation from the US Food and Drug Administration (FDA) and is in discussions with other global regulatory bodies for the approval of its JN.1 Covid-19 vaccine. NVX-CoV2705 is a modified formulation of Novavax's original Co
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
- New Covid Shots Recommended for Americans 6 Months and Older This Fall [The New York Times]The New York Times
- Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe [Yahoo! Finance]Yahoo! Finance
- Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 VaccinePR Newswire
- Novavax (NVAX) Ascends While Market Falls: Some Facts to Note [Yahoo! Finance]Yahoo! Finance
NVAX
Earnings
- 2/28/24 - Miss
NVAX
Analyst Actions
- 5/13/24 - HC Wainwright
NVAX
Sec Filings
- 6/25/24 - Form 4
- 6/21/24 - Form 4
- 6/20/24 - Form 4
- NVAX's page on the SEC website